The New England Journal of Medicine
This week, we will discuss the MENTOR trial, which pitted rituximab versus cyclosporine for membranous nephropathy
This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.
Can PIVOTAL pivot us to pump more iron? It is indeed a pivot from the lazy, halycon days of the ESA era, now to the evil ESA empire crumbling under the strong iron attack. Join us to discuss!
The fault, is not in our stars, or in our environment, but sometimes in ourselves. Nature, not just nurture, is more important than we knew. Join us, as we try to undertand the implications of this new research suggesting how many CKD cases have genetic underpinnings.
Randomized controlled trial of restrictive versus liberal IV fluid strategy around abdominal surgery.
This week, we will discuss the NEJM cluster RCT from Victor and colleagues, which has created such a buzz. Barbers and pharmacists team to have a fantastic effect. Could it be true?
March 13/14 we will discuss the pair of trials in NEJM from Vanderbilt: comparing balanced solutions to normal saline in critically ill & not ill patients. Join us for the next #NephJC to parse through SMART & SALT-ED
What's the risk of ESKD after a child has a resolved nephrology issue in childhood? Israeli military records answer the question.
This week, we will discuss the fresh-off-the-press NEJM paper on the utility of using NAC (vs placebo) or bicarb-based hydration (vs saline) in preventing contrast AKI. A medical reversal that has taken almost 2 decades...
This week, we will discuss the fresh-off-the-press and fresh from KidneyWk REPRISE trial, which was also presented at the late breaking clinical trial session. Join us to discuss the nitty-gritty on Nov 14th and 15th
Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.
JAMA: Journal of the American Medical Association
This week, we will discuss a perspective peice looking at the use of race in the eGFR formulas routinely used in the hospital. #NephJC chat.
First chat of 2019 - showcasing again the honest brokers of nephrology trials with another negative trial. Also note we will be having a NephJC Asia chat starting this week!
This week, we will discuss the use of lanreotide - a somoatostatin analogue, for the treatment of autosomal dominant polycystic kidney disease. An RCT, published in JAMA.
How much water should we drink? Does drinking more water help flush the kidney? Join us as we discuss the definitive trial done to answer this question.
This week, we will discuss the JAMA paper on disparities in living donor kidney transplant *rates* across race/ethnicities. There is a parallel paper from the UK, which shows somewhat similar findings. Join us Feb 6 and 7 to discuss on #NephJC!
Join us Dec 19 and 20 as we discuss the MYRE trial from JAMA. Using a high cutoff dialyzer and removing light chains to help the kidneys heal faster
Protocol sepsis management has had a rough few years. Another failure trial, this time from Zambia.
Stop-IgAN suggested steroids may not be useful in patients with intermediate range proteinuria. Now, in a different population with more proteinuria, TESTING finds a mixed result: some benfit + more adverse events. Should we keep on TESTING?